Welcome to our dedicated page for Harvard Biosci SEC filings (Ticker: HBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harvard Bioscience, Inc. (HBIO) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including Forms 10‑K, 10‑Q, 8‑K and other key documents. Harvard Bioscience is a developer, manufacturer and seller of technologies, products and services used in life science research, drug and therapy discovery, bio‑production and preclinical testing. Its filings provide detailed information on this business, its financial condition and its capital structure.
Through annual reports on Form 10‑K and quarterly reports on Form 10‑Q, Harvard Bioscience presents audited and interim financial statements, segment and product discussions, risk factors, management’s discussion and analysis, and information on liquidity and capital resources. These filings give investors and analysts insight into revenues, margins, operating expenses, cash flows and balance sheet items, as well as commentary on trends affecting its life science tools business.
Current reports on Form 8‑K are especially important for tracking material events at Harvard Bioscience. In 2025, the company used 8‑K filings to disclose amendments to its credit agreement, a new Loan and Security Agreement with BroadOak that introduced term loans and a convertible term loan, the issuance of warrants, Nasdaq listing and compliance notices, audit committee composition matters, retention arrangements with executives, and the announcement of quarterly financial results and conference calls. These 8‑K filings also document board appointments and CEO succession plans.
On this page, Stock Titan provides real‑time access to new HBIO filings as they appear on EDGAR, along with AI‑generated summaries that explain the core points of each document in plain language. For example, AI summaries can highlight covenant changes and going‑concern language in credit‑related filings, outline the structure of new financing arrangements, or extract key performance metrics from earnings releases furnished on Form 8‑K. Users can also review insider transaction reports on Form 4 when available, to see equity awards or share transactions by directors and officers as disclosed in SEC filings.
By consolidating Harvard Bioscience’s 10‑K, 10‑Q, 8‑K and other SEC forms with AI‑assisted analysis, this page helps readers understand how the company reports on its life science tools operations, capital structure, Nasdaq listing status and governance changes over time, without having to parse every filing manually.